Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Pharmaceutical
While AstraZeneca’s chief executive Pascal Soriot has been proven right about many of his prior boasts on the company’s future success during his 12-year reign, his latest claim could be questioned even by his strongest supporters. 21 May 2024
Biotechnology
The European Commission (EC) has decided not to adopt the European Medicines Agency’ human medicines committee CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren) and has returned the opinion to the CHMP for re-evaluation. 21 May 2024
Biotechnology
Shares of Massachusetts, USA-based muscle specialist Dyne Therapeutics closed up almost 28% at $35.38 yesterday, after it released positive clinical data from its ongoing Phase I/II ACHIEVE trial of DYNE-101. 21 May 2024
Biotechnology
Swiss family-owned protein specialist Octapharma has appointed pharmaceutical industry veteran Kelly Hearn as vice president of commercial development and marketing of its American company, Octapharma USA.
Ms Hearn will take immediate leadership 20 May 2024
Pharmaceutical
Japanese drugmaker Otsuka has announced that the primary endpoint was achieved in the Phase III trial in Japan of bempedoic acid as a potential treatment for patients with hypercholesterolemia. 20 May 2024
Biotechnology
Inaugurated last Friday (May 17), the Pasteur Fiocruz Center on Immunology and Immunotherapy, located at Fiocruz Ceará, brings together scientists from the France-based Institut Pasteur and Brazil’s Fiocruz, two members of the Pasteur Network, to develop an integrative approach towards immunotherapies applied to both infectious and non-communicable diseases. 20 May 2024
Biotechnology
On the deal-making front last week, US rare disease focused biotech Fulcrum Therapeutics out-licensed ex-USA rights for its muscular dystrophy candidate losmapimod to French pharma major Sanofi for a modest $80 million upfront but with a further $975 million on the line. Research developments included US biotech Cytokinetics releasing Phase III data on its investigational cardiomyopathy drug aficamten, while US biotech major Biogen pulled the plug on two antisense oligonucleotide programs – BIIB105 and BIIB121 – being developed with Ionis Pharmaceutical. Also of note, Blackstone Life Sciences un-stealthed Uniquity Bio with a US Food and Drug Administration (FDA)-accepted investigational new drug (IND) for the monoclonal antibody solrikitug and $300 million financing. 19 May 2024
Biotechnology
American biopharma company Biogen is to pull the plug on two antisense oligonucleotide (ASO) programs. 17 May 2024
Biotechnology
Positive high-level results have been presented from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial of AstraZeneca’s sipavibart. 16 May 2024
Biotechnology
Blackstone has announced the launch of the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug developer on immunology and inflammation. 16 May 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze